Home › Funds › RA CAPITAL MANAGEMENT, L.P. › CLYM

RA CAPITAL MANAGEMENT, L.P. position in CLYM

CLIMB BIO INC · Health Care

RA CAPITAL MANAGEMENT, L.P. reported holding 11,300,939 shares of CLYM (CLIMB BIO INC) in its Q2 2026 13F filing — a position valued at US$147.4M, representing 1.28% of its reported portfolio and ranking #24 among its reported holdings. RA CAPITAL MANAGEMENT, L.P. has disclosed CLYM holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)11.30M sh
Reported value held$147.36M
Portfolio Weight1.28%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How RA CAPITAL MANAGEMENT, L.P.'s CLYM position evolved

RA CAPITAL MANAGEMENT, L.P. first disclosed a stake in CLYM in Q3 2023 at 13,150,849 shares (US$34.6M). The position peaked in Q2 2024 at 31,419,267 shares, worth US$223.4M. Across 12 filings, RA CAPITAL MANAGEMENT, L.P. increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 9 time(s). The most recent filing (Q2 2026) shows 11,300,939 shares valued at US$147.4M. Notable position changes include a 139% increase in Q2 2024 (shares fell 28% over the following quarter), a 64% trim in Q4 2025 (shares rose 71% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 13.15M $34.59M New
Q4 2023 13.15M $35.51M Hold
Q1 2024 13.15M $36.03M Hold
Q2 2024 31.42M $223.39M Add
Q3 2024 31.42M $159.92M Hold
Q4 2024 31.42M $56.55M Hold
Q1 2025 31.42M $38.33M Hold
Q2 2025 31.42M $38.96M Hold
Q3 2025 31.42M $63.15M Hold
Q4 2025 11.29M $77.71M Reduce
Q1 2026 11.30M $77.41M Hold
Q2 2026 11.30M $147.36M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CLYM and 13F data

CLYM (CLIMB BIO INC) is a Health Care company. 75 other funds we track also report a position in CLYM — the largest reported positions include BRAIDWELL LP (US$36.5M), Cormorant Asset Management, LP (US$27.5M), Redmile Group, LLC (US$16.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CLYM

All CLYM fund holders →

FAQ

How long has RA CAPITAL MANAGEMENT, L.P. held CLYM?

RA CAPITAL MANAGEMENT, L.P. has disclosed CLYM holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is RA CAPITAL MANAGEMENT, L.P.'s current position in CLYM?

As of Q2 2026, RA CAPITAL MANAGEMENT, L.P. holds 11.30M shares of CLYM (CLIMB BIO INC), valued at $147.36M, representing 1.28% of its reported portfolio and ranking #24.

Has RA CAPITAL MANAGEMENT, L.P. been buying or selling CLYM?

In the latest 13F filing (Q2 2026), RA CAPITAL MANAGEMENT, L.P. held unchanged its position in CLYM. The position peaked in Q2 2024 at 31.42M shares.

Which other funds hold CLYM?

Other major institutional holders of CLYM include BRAIDWELL LP, Cormorant Asset Management, LP, Redmile Group, LLC, among 75 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.